| Pair Name | Epifriedelanol, Doxorubicin | ||
| Phytochemical Name | Epifriedelanol (PubChem CID: 119242 ) | ||
| Anticancer drug Name | Doxorubicin (PubChem CID: 31703 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Epifriedelanol, Doxorubicin | |||
| Disease Info | [ICD-11: 2B33.2] | Chronic myeloid leukemia | Investigative | |
| Gene Regulation | Down-regulation | Expression | ABCB1 | hsa5243 |
| Down-regulation | Expression | ABCC2 | hsa1244 | |
| Up-regulation | Expression | CXADR | hsa1525 | |
| Up-regulation | Expression | NR1I2 | hsa8856 | |
| In Vitro Model | K562/Adr | Blast phase chronic myelogenous leukemia | Homo sapiens (Human) | CVCL_3827 |
| Result | The present study demonstrated that Epi could enhance Adr-induced cytotoxicity towards K562/ADM cells accompanied by the down-regulation of P-gp and MRP2. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Epifriedelanol enhances adriamycin-induced cytotoxicity towards K562/ADM cells by down regulating of P-gp and MRP2. Xenobiotica. 2022 Apr;52(4):389-396. doi: 10.1080/00498254.2022.2079441. | Click |
